Advisory - Unauthorized health product "Blow" may pose serious health risks
OTTAWA, Jan. 16, 2017 /CNW/ -
Issue Health Canada is advising Canadians that it has seized the unauthorized health product "Blow," by Limitless Pharma, from Atomik Nutrition at 450 Boulevard de Mortagne, Boucherville, QC.
"Blow" is promoted as a pre-workout supplement and is labelled to contain the unauthorized drug 1,3?Dimethylamylamine (DMAA), which may pose serious health risks such as high blood pressure and stroke.
Who is affected
Consumers who have bought or used this product.
Affected product
"Blow," by Limitless Pharma.
What consumers should do
Stop using this product. Consult with your health care professional if you have used this product and have health concerns.
Read product labels to verify that health products have been authorized for sale by Health Canada. Authorized health products have an eight-digit DIN, DIN-HM or NPN. You can also check if products have been authorized for sale by searching Health Canada's Drug Product Database and Licensed Natural Health Product Database.
Report adverse events to health products to Health Canada by calling toll-free at 1?866?234?2345, or by reporting online, by mail or by fax.
Report complaints about health products to Health Canada by calling toll-free at 1?800?267?9675, or complete an online complaint form.
Background 1,3-Dimethylamylamine (DMAA) is a drug that is not authorized for use in Canada. Side effects include high blood pressure, shortness of breath, chest pain, stroke and psychiatric disorders.
What Health Canada is doing Health Canada seized the product from the retail location after receiving a consumer complaint. Should additional retailers or distributors be identified, Health Canada will take appropriate action and inform Canadians.
For more information Stay connected with Health Canada and receive the latest advisories and product recalls using social media tools.
To learn more about natural health products and other self-care products, visit Canada.ca/selfcare-products.
The global gastroesophageal reflux disease (GERD) market size is estimated to grow by USD 879.8 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 3.2% during the forecast period. Rising geriatric...
Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distribution agreement with Ascendis Pharma A/S ("Ascendis"), a global biopharmaceutical company headquartered in Copenhagen, Denmark. Under the terms of...
Imperial Tobacco Canada Limited ("ITCAN") has officially submitted its feedback to Health Canada regarding the proposed Ministerial Order on nicotine replacement therapy products (NRTs). ITCAN strongly believes that NRTs, especially innovative...
The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.
Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented...
The "Diagnostic Imaging Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.
Diagnostic Imaging Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...
King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of...